IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

(2021) Yun Liang et al.   Journal of Hematology & Oncology

Recent advances in CAR-T cell engineering

(2020) Ruihao Huang et al.   Journal of Hematology & Oncology

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

(2019) Jiang Lv et al.   Journal of Hematology & Oncology

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia

(2018) Jianyu Weng et al.   Journal of Hematology & Oncology

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

(2018) Keishi Adachi et al.   NATURE BIOTECHNOLOGY

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells

(2017) Y Lai et al.   LEUKEMIA

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor

(2016) Xuemei Jiang et al.   Frontiers in Immunology